Objective To explore the clinical effect of single high-dose intravenous infusion of Human Immunoglobulin in the treatment of neonatal ABO hemolytic disease.Methods A total of 78 newborns with neonatal ABO hemolytic disease treated in the Department of Neonatology,Xianxian Hospital of Traditional Chinese Medicine from January 2019 to June 2023 were selected as the study objects.All the newborns were divided into the group A(39 cases)and the group B(39 cases)according to the lottery method.The group A received single high-dose intravenous infusion of Human Immunoglobulin,while the group B received twice low-dose intravenous injections of Human Immunoglobulin.The levels of total bilirubin(TBil),hospitalization time,incidence of adverse reactions,and immune function of the two groups were compared.Results At 24,48,and 72 hours of treatment,the TBil levels in both groups were lower than those before treatment,and the level of the group A was lower than that of the group B,the difference was statistically significant(P<0.05).The hospitalization time of the group A was shorter than that of the group B(P<0.05).After treatment,the levels of immunoglobulin G and immunoglobulin A in both groups were increased,and the levels of the group A were higher than those of the group B(P<0.05).Conclusion Single high-dose intravenous infusion of Human Immunoglobulin is more effective in the treatment of neonatal ABO hemolytic disease,which can improve the immune function without increasing adverse reactions.
关键词
新生儿ABO溶血病/静脉滴注人免疫球蛋白/免疫功能
Key words
Neonatal ABO hemolytic disease/Intravenous infusion of Human Immunoglobulin/Immune function
维普
万方数据